Parsaclisib Shows Promise in Easing Sjögren’s Symptoms in Mouse Models

Parsaclisib Shows Promise in Easing Sjögren’s Symptoms in Mouse Models

302416

Parsaclisib Shows Promise in Easing Sjögren’s Symptoms in Mouse Models

The findings of a new study support the development of Incyte‘s parsaclisib as a potential therapy for Sjögren’s syndrome and other autoimmune diseases. Parsaclisib, an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, was found to ease the symptoms of Sjögren’s and other disorders in a study using mouse models. That study, “The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren’s syndrome,” was published in International Immunopharmacology. It…

You must be logged in to read/download the full post.